2023
National Patterns of Early Adoption of Magnetic Resonance Imaging–Guided Linear Accelerators in 2018 to 2019
Yu J, Kinslow C, Cheng S, Ellis R, Horowitz D. National Patterns of Early Adoption of Magnetic Resonance Imaging–Guided Linear Accelerators in 2018 to 2019. Advances In Radiation Oncology 2023, 8: 101167. PMID: 36798607, PMCID: PMC9926207, DOI: 10.1016/j.adro.2022.101167.Peer-Reviewed Original ResearchNational Cancer DatabaseIntensity modulated radiation therapyFood and Drug Administration approvalSite of diseaseImprove radiation treatmentDrug Administration approvalFood and Drug AdministrationSample of patientsRadiation therapyLinear acceleratorCancer DatabaseAdministration approvalDisease sitesRadiation treatmentComprehensive cancer centerAcademic centersCancer CenterDrug AdministrationPatientsPractice patternsTherapyCancer sitesAdapt treatmentImproved visualizationBreast
2022
Prediction of Distant Metastases After Stereotactic Body Radiation Therapy for Early Stage NSCLC: Development and External Validation of a Multi-Institutional Model
Gao S, Jin L, Meadows H, Shafman T, Gross C, Yu J, Aerts H, Miccio J, Stahl J, Mak R, Decker R, Kann B. Prediction of Distant Metastases After Stereotactic Body Radiation Therapy for Early Stage NSCLC: Development and External Validation of a Multi-Institutional Model. Journal Of Thoracic Oncology 2022, 18: 339-349. PMID: 36396062, DOI: 10.1016/j.jtho.2022.11.007.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyEarly-stage NSCLCBody radiation therapyDistant metastasisStage NSCLCRadiation therapyHigh-risk patient subgroupsExternal validationPatient-level riskMulti-institutional databaseTime-dependent areaGray regression modelsRandom survival forest modelDM riskSystemic therapyPatient subgroupsIndividualized riskNSCLCPatientsDM ratesDiscriminatory performanceRandom survival forestTherapyInternal validationGood calibrationPractice Patterns Related to Mitigation of Neurocognitive Decline in Patients Receiving Whole Brain Radiation Therapy
Jairam V, Park HS, Yu JB, Bindra RS, Contessa JN, Jethwa KR. Practice Patterns Related to Mitigation of Neurocognitive Decline in Patients Receiving Whole Brain Radiation Therapy. Advances In Radiation Oncology 2022, 7: 100949. PMID: 35521071, PMCID: PMC9065721, DOI: 10.1016/j.adro.2022.100949.Peer-Reviewed Original ResearchWhole-brain radiation therapyBrain radiation therapyRadiation oncologistsPractice patternsRadiation therapyHA-WBRTNeurocognitive declineCommon reasonHippocampal avoidance whole brain radiation therapyNational practice patternsDeleterious cognitive effectsRoutine clinical practiceNeurocognitive preservationBrain metastasesTreatment delayProvider characteristicsEffective treatmentCurrent evidencePearson χMemantineClinical practicePatientsPrior authorizationMajority of respondentsTherapy
2020
Development and External Validation of a Nomogram to Predict Distant Metastases after Stereotactic Body Radiation Therapy in Early Stage Non-Small Cell Lung Cancer Patients
Gao S, Dosoretz A, Shafman T, Gross C, Yu J, Meadows H, Decker R, Mak R, Kann B. Development and External Validation of a Nomogram to Predict Distant Metastases after Stereotactic Body Radiation Therapy in Early Stage Non-Small Cell Lung Cancer Patients. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e90. DOI: 10.1016/j.ijrobp.2020.07.1190.Peer-Reviewed Original ResearchRadiation Dose to the Rectum With Definitive Radiation Therapy and Hydrogel Spacer Versus Postprostatectomy Radiation Therapy
Yang DX, Verma V, An Y, Yu JB, Sprenkle PC, Leapman MS, Park HS. Radiation Dose to the Rectum With Definitive Radiation Therapy and Hydrogel Spacer Versus Postprostatectomy Radiation Therapy. Advances In Radiation Oncology 2020, 5: 1225-1231. PMID: 33305083, PMCID: PMC7718530, DOI: 10.1016/j.adro.2020.08.015.Peer-Reviewed Original ResearchDefinitive radiation therapyPostoperative radiation therapyHydrogel spacerRadiation therapyRectal dosimetryProstate cancerGroup 1Rectal dose-volume parametersPostprostatectomy radiation therapyDose-volume parametersPostprostatectomy settingSurgical patientsPrimary managementRectal volumeDefinitive settingRadical prostatectomyRectal dosesGroup 2High riskPatientsLinear regression analysisProstatectomyMann-WhitneyTherapyCancerTrends in Use and Comparison of Stereotactic Body Radiation Therapy, Brachytherapy, and Dose-Escalated External Beam Radiation Therapy for the Management of Localized, Intermediate-Risk Prostate Cancer
Nguyen KA, Lee A, Patel SA, Chakravorty A, Yu JB, Kishan AU, Chang AJ. Trends in Use and Comparison of Stereotactic Body Radiation Therapy, Brachytherapy, and Dose-Escalated External Beam Radiation Therapy for the Management of Localized, Intermediate-Risk Prostate Cancer. JAMA Network Open 2020, 3: e2017144. PMID: 32970153, PMCID: PMC7516602, DOI: 10.1001/jamanetworkopen.2020.17144.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyBody radiation therapyRadiation therapyProstate cancerIntermediate-risk prostate cancerExternal beam radiation therapyManagement of LocalizedExternal beam radiotherapyUse of brachytherapyBeam radiation therapyCohort studyBeam radiotherapyTherapyDisease managementCancerBrachytherapyPatientsRadiotherapyUtilization of next-generation sequencing and associated systemic therapy initiation in metastatic prostate cancer.
Yang D, Leapman M, Gross C, Yu J. Utilization of next-generation sequencing and associated systemic therapy initiation in metastatic prostate cancer. Journal Of Clinical Oncology 2020, 38: e19308-e19308. DOI: 10.1200/jco.2020.38.15_suppl.e19308.Peer-Reviewed Original ResearchMetastatic prostate cancerSystemic therapy initiationTherapy initiationNGS test resultsNGS testingSystemic therapyMetastatic diagnosisNGS testsProstate cancerCommon systemic therapySystemic therapy selectionRetrospective observational studyNext-generation sequencing testDe-identified databaseMPC patientsTherapy startClinical outcomesMedian timeTherapy changesTreatment choiceObservational studyTherapy selectionGenomic classifierPatientsTherapyUltrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: A systematic review and meta-analysis of phase III randomized trials
Lehrer E, Kishan A, Yu J, Trifiletti D, Showalter T, Ellis R, Zaorsky N. Ultrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: A systematic review and meta-analysis of phase III randomized trials. Radiotherapy And Oncology 2020, 148: 235-242. PMID: 32505965, DOI: 10.1016/j.radonc.2020.04.037.Peer-Reviewed Original ResearchConceptsConventionally fractionated radiation therapyHypofractionated radiation therapyUltrahypofractionated radiation therapyLate grade 2Radiation therapyGrade 2Weighted random effects meta-analysesSummary effect sizesLocalized prostate cancerCompare treatment modalitiesDerSimonian and Laird methodPhase III protocolsRandom-effects meta-analysesGenitourinary toxicityEffects meta-analysesGastrointestinal toxicityProspective trialsMedian ageProstate cancerTreatment modalitiesComparing patientsIII protocolLaird methodTherapyMeta-analysis
2019
An Externally Validated Nomogram to Predict Distant Metastases after Stereotactic Body Radiation Therapy in Early Stage Non-Small Cell Lung Cancer Patients
Gao S, Kann B, Dosoretz A, Shafman T, Gross C, Yu J, Decker R. An Externally Validated Nomogram to Predict Distant Metastases after Stereotactic Body Radiation Therapy in Early Stage Non-Small Cell Lung Cancer Patients. International Journal Of Radiation Oncology • Biology • Physics 2019, 105: s145-s146. DOI: 10.1016/j.ijrobp.2019.06.146.Peer-Reviewed Original ResearchCost-Effectiveness of Prostate Radiation Therapy in Men with Newly Diagnosed Low Burden Metastatic Prostate Cancer
Lester-Coll N, Ades S, Yu J, Atherly A, Wallace H, Sprague B. Cost-Effectiveness of Prostate Radiation Therapy in Men with Newly Diagnosed Low Burden Metastatic Prostate Cancer. International Journal Of Radiation Oncology • Biology • Physics 2019, 105: s180-s181. DOI: 10.1016/j.ijrobp.2019.06.221.Peer-Reviewed Original ResearchStereotactic Body Radiation Therapy Vs Hypofractionated Intensity Modulated Radiation Therapy for Localized Prostate Cancer (SHRAPNEL): An International Meta-Analysis of 24 Prospective Trials
Lehrer E, Kishan A, Yu J, Trifiletti D, Showalter T, Ellis R, Zaorsky N. Stereotactic Body Radiation Therapy Vs Hypofractionated Intensity Modulated Radiation Therapy for Localized Prostate Cancer (SHRAPNEL): An International Meta-Analysis of 24 Prospective Trials. International Journal Of Radiation Oncology • Biology • Physics 2019, 105: e289. DOI: 10.1016/j.ijrobp.2019.06.1829.Peer-Reviewed Original ResearchComparative Effectiveness of SBRT
Aneja S, Kumar R, Yu J. Comparative Effectiveness of SBRT. 2019, 415-424. DOI: 10.1007/978-3-030-16924-4_34.Peer-Reviewed Original ResearchStereotactic body radiation therapyAlternative treatment modalityBody radiation therapyComparative effectiveness studiesCost-effectiveness studiesLarge database analysisRetrospective seriesTreatment modalitiesRadiation therapySBRT treatmentComparative effectivenessEffectiveness studiesDatabase analysisStereotactic treatmentTreatmentPatientsLungTherapyProstateLiverBrainPV-0045 Is proton therapy a "pro" for breast cancer? A comparison of proton vs. non-proton RT using the NCDB
Chowdhary M, Lee A, Gao S, Barry P, Diaz R, Bagadiya N, Park H, Yu J, Wilson L, Moran M, Higgins S, Knowlton C, Patel K. PV-0045 Is proton therapy a "pro" for breast cancer? A comparison of proton vs. non-proton RT using the NCDB. Radiotherapy And Oncology 2019, 133: s15. DOI: 10.1016/s0167-8140(19)30465-7.Peer-Reviewed Original ResearchModerate hypofractionation and stereotactic body radiation therapy in the treatment of prostate cancer
Beckta J, Nosrati J, Yu J. Moderate hypofractionation and stereotactic body radiation therapy in the treatment of prostate cancer. Urologic Oncology Seminars And Original Investigations 2019, 37: 619-627. PMID: 30738746, DOI: 10.1016/j.urolonc.2019.01.015.Peer-Reviewed Original ResearchConceptsModerate hypofractionationRadiation therapyStereotactic body radiation therapyProstate cancer radiation therapyTreatment of prostate cancerCancer radiation therapyReduced duration of treatmentDuration of treatmentStandard of careCurative intentProstate cancerHigh dosesHypofractionationReduced durationDaily sessionsFractionation schemeTherapyEffective alternativeTreatmentProstatePatientsCancerDoseMonthsCareRadiation Therapy for Renal Cell Carcinoma
Choi R, Yu J. Radiation Therapy for Renal Cell Carcinoma. Kidney Cancer 2019, Preprint: 1-6. DOI: 10.3233/kca-180040.Peer-Reviewed Original ResearchRenal cell carcinomaTreatment of renal cell carcinomaStereotactic ablative radiotherapyRadiation therapyCell carcinomaAdjuvant treatment of renal cell carcinomaAblative radiotherapyAdjuvant treatmentTreatment optionsHigh dosesTherapyCarcinomaTargets of diseaseTreatmentRT’s roleRadiotherapyCancerDose
2018
Treatment-Related Complications of Chemotherapy and Radiation Therapy: An Analysis of the Nationwide Emergency Department Sample
Jairam V, Park H, Yu J. Treatment-Related Complications of Chemotherapy and Radiation Therapy: An Analysis of the Nationwide Emergency Department Sample. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: e416-e417. DOI: 10.1016/j.ijrobp.2018.07.1221.Peer-Reviewed Original ResearchSystemic Therapy with Stereotactic Body Radiation Therapy (SBRT) for Early-Stage Non-Small Cell Lung Carcinoma (NSCLC): A Multi-institutional Analysis
Kann B, Miccio J, Stahl J, Verma V, Dosoretz A, Park H, Shafman T, Gross C, Yu J, Decker R. Systemic Therapy with Stereotactic Body Radiation Therapy (SBRT) for Early-Stage Non-Small Cell Lung Carcinoma (NSCLC): A Multi-institutional Analysis. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: s10-s11. DOI: 10.1016/j.ijrobp.2018.06.119.Peer-Reviewed Original ResearchComplementary Medicine, Refusal of Conventional Cancer Therapy, and Survival among Patients with Curable Cancers
Johnson S, Park H, Gross C, Yu J. Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival among Patients with Curable Cancers. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: e399-e400. DOI: 10.1016/j.ijrobp.2018.07.1180.Peer-Reviewed Original ResearchBladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer
Johnson S, Yu J. Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer. Current Oncology Reports 2018, 20: 66. PMID: 29959582, DOI: 10.1007/s11912-018-0711-0.Peer-Reviewed Original ResearchConceptsBladder-preserving trimodality therapyTrimodality therapyRadical cystectomyBladder cancerMuscle-invasive urothelial carcinomaMuscle-invasive bladder cancerAlternative to cystectomySatisfactory quality of lifeBladder preservationOncological outcomesUrothelial carcinomaCystectomyFuture trialsBladderFunctional outcomesTherapyDisease outcomePatientsQuality of lifeTrimodalityCancerOutcomesCarcinoma
2017
RTHP-16. PATTERNS OF TREATMENT AND OUTCOMES OF 1p19q CO-DELETED GLIOMAS
Yeboa D, Yu J, Huse J, Penas-Prado M, Sulman E, Contessa J. RTHP-16. PATTERNS OF TREATMENT AND OUTCOMES OF 1p19q CO-DELETED GLIOMAS. Neuro-Oncology 2017, 19: vi222-vi222. PMCID: PMC5692027, DOI: 10.1093/neuonc/nox168.900.Peer-Reviewed Original ResearchGrade III tumorsCombined-modality therapyRadiation therapyCox multivariable proportional hazards modelMultivariable proportional hazards modelsNational Cancer DatabasePatterns of treatmentGrade II tumorsPatterns of carePost-operative therapyProportional hazards modelLow-grade gliomasOverall survivalII tumorsHistologic gradeCancer DatabaseTumor gradeGrade IITreatment outcomesAdditional molecular characterizationHazards modelGrade gliomasPatientsTherapyGliomas